Tibulizumab not checked

Zura Bio Inc · ZB-106

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total · 2 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
Tested for
Hidradenitis Suppurativa (HS), Systemic Sclerosis (SSc), Scleroderma
Main trialPhase 2
“The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)”In the company’s words, NCT06993610 on ClinicalTrials.gov
Other names
ZB-106

Other drugs for Hidradenitis Suppurativa (HS)

All 29 drugs for Hidradenitis Suppurativa (HS)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 18 Sep 2026 Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
Phase 2Active, not recruiting May 2027 Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Tibulizumab

Following is part of Solo: you see every change to Tibulizumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in